JP7590737B2 - ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞 - Google Patents

ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞 Download PDF

Info

Publication number
JP7590737B2
JP7590737B2 JP2021547571A JP2021547571A JP7590737B2 JP 7590737 B2 JP7590737 B2 JP 7590737B2 JP 2021547571 A JP2021547571 A JP 2021547571A JP 2021547571 A JP2021547571 A JP 2021547571A JP 7590737 B2 JP7590737 B2 JP 7590737B2
Authority
JP
Japan
Prior art keywords
cd1a
cell
domain
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021547571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520455A (ja
JP2022520455A5 (https=
JPWO2020165350A5 (https=
Inventor
ブハン パブロ メネンデス
マルティネス ディエゴ サンチェス
ウロス クララ ブエノ
アグエラ フランシスコ グティエレス
ヘレイア ロカ－オ
Original Assignee
フンダシオン インスティテュート デ インヴェスティガシオン コントラ ラ レウセミア ジュゼップ カレラス （アイジェイシー）
インスティトゥシオ カタラーナ デ レセルカ イ エストゥディス アバンカツ （アイシーアールイーエー）
フンダシオ インスティテュート ディンベスティガシオ エン シエンシエス デ ラ サリュ ジャーマンス トライアス アイ プジョル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フンダシオン インスティテュート デ インヴェスティガシオン コントラ ラ レウセミア ジュゼップ カレラス （アイジェイシー）, インスティトゥシオ カタラーナ デ レセルカ イ エストゥディス アバンカツ （アイシーアールイーエー）, フンダシオ インスティテュート ディンベスティガシオ エン シエンシエス デ ラ サリュ ジャーマンス トライアス アイ プジョル filed Critical フンダシオン インスティテュート デ インヴェスティガシオン コントラ ラ レウセミア ジュゼップ カレラス （アイジェイシー）
Publication of JP2022520455A publication Critical patent/JP2022520455A/ja
Publication of JP2022520455A5 publication Critical patent/JP2022520455A5/ja
Publication of JPWO2020165350A5 publication Critical patent/JPWO2020165350A5/ja
Priority to JP2024195152A priority Critical patent/JP2025024031A/ja
Application granted granted Critical
Publication of JP7590737B2 publication Critical patent/JP7590737B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4213—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021547571A 2019-02-14 2020-02-13 ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞 Active JP7590737B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024195152A JP2025024031A (ja) 2019-02-14 2024-11-07 ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382104.8 2019-02-14
EP19382104.8A EP3696191A1 (en) 2019-02-14 2019-02-14 Car t-cells for the treatment of cd1a-positive cancer
PCT/EP2020/053769 WO2020165350A1 (en) 2019-02-14 2020-02-13 Car t-cells for the treatment of cd1a-positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024195152A Division JP2025024031A (ja) 2019-02-14 2024-11-07 ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞

Publications (4)

Publication Number Publication Date
JP2022520455A JP2022520455A (ja) 2022-03-30
JP2022520455A5 JP2022520455A5 (https=) 2023-02-21
JPWO2020165350A5 JPWO2020165350A5 (https=) 2023-02-21
JP7590737B2 true JP7590737B2 (ja) 2024-11-27

Family

ID=65685281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021547571A Active JP7590737B2 (ja) 2019-02-14 2020-02-13 ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞
JP2024195152A Pending JP2025024031A (ja) 2019-02-14 2024-11-07 ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024195152A Pending JP2025024031A (ja) 2019-02-14 2024-11-07 ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞

Country Status (8)

Country Link
US (1) US12215158B2 (https=)
EP (2) EP3696191A1 (https=)
JP (2) JP7590737B2 (https=)
CN (2) CN118436770A (https=)
AU (1) AU2020222239B2 (https=)
CA (1) CA3128955A1 (https=)
MX (1) MX2021009798A (https=)
WO (1) WO2020165350A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
US11746154B2 (en) 2020-10-09 2023-09-05 Pfizer Inc. CD1a antibodies and uses thereof
AU2022282828A1 (en) * 2021-05-26 2023-12-14 Oxford University Innovation Limited Antibodies
IT202100027929A1 (it) * 2021-11-02 2023-05-02 Univ Degli Studi Magna Graecia Di Catanzaro Un nuovo anticorpo bispecifico asimmetrico(UMG2/CD1a-CD3e) per il trattamento immunologico della forma corticale di leucemia linfoblastica acuta T (T-ALL) pediatrica e dell’adulto
EP4234582A1 (en) * 2022-02-28 2023-08-30 Onechain Immunotherapeutics SL Humanized cd1a targeting moiety for the treatment of cd1a-positive cancer
CA3251493A1 (en) * 2022-02-28 2023-08-31 Onechain Immunotherapeutics S.L Humanized CD1A Targeting Fraction for Treating CD1A-Positive Cancer
GB202217923D0 (en) * 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies
EP4417623A1 (en) * 2023-02-15 2024-08-21 Fundació Institut de Recerca Contra la Leucèmia Josep Carreras Ccr9 targeting moiety for the treatment of ccr9-positive cancer
EP4545085A1 (en) * 2023-10-26 2025-04-30 Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz Car t-cells against cd79b for the treatment of non-hodgkin lymphoma
CN119685260B (zh) * 2024-12-17 2026-01-13 上海交通大学医学院附属瑞金医院 一种具有新型穿膜区的嵌合抗原受体t细胞及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522833A (ja) 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
GB0717101D0 (en) * 2007-09-03 2007-10-10 Cambridge Entpr Ltd Tumour marker
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018522833A (ja) 2015-06-12 2018-08-16 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． キメラ抗原受容体（ｃａｒ）コンストラクト、及びｃａｒコンストラクトを発現するｔ細胞（ｃａｒ−ｔ）またはｎｋ細胞（ｃａｒ−ｎｋ）による疾患治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EXPERIMENTAL HEMATOLOGY，2018年08月22日，Vol. 64, No. 22，p. S85, 3107
JOURNAL OF INVESTIGATIVE DERMATOLOGY，2000年，Vol . 114, No. 1，p. 127-134
KLINISCHE PAEDIATRIE，2018年04月01日，Vol. 230, No. 3，p. 174, 39

Also Published As

Publication number Publication date
JP2022520455A (ja) 2022-03-30
US12215158B2 (en) 2025-02-04
MX2021009798A (es) 2021-11-17
AU2020222239A1 (en) 2021-10-07
JP2025024031A (ja) 2025-02-19
AU2020222239B2 (en) 2024-12-05
EP3696191A1 (en) 2020-08-19
CN113795506A (zh) 2021-12-14
CN118436770A (zh) 2024-08-06
EP3924374A1 (en) 2021-12-22
CA3128955A1 (en) 2020-08-20
US20220143085A1 (en) 2022-05-12
WO2020165350A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP7590737B2 (ja) ＣＤ１ａ陽性癌の治療のためのＣＡＲ Ｔ細胞
JP7352473B2 (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
AU2015317608B2 (en) Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP2024513262A (ja) Ｎｋｐ４６及びｃｄ３８を標的とする二重特異性抗体、並びにその使用方法
JP7729561B2 (ja) 多発性骨髄腫治療用の抗ｂｃｍａ ｃａｒ ｔ細胞
JP7545139B2 (ja) Ｂ細胞急性リンパ芽球性白血病（ｂ－ａｌｌ）の処置のためのｃｄ２２標的化部分
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
US20260116982A1 (en) Car t-cells for the treatment of cd1a-positive cancer
HK40116152A (zh) 用於治疗cd1a阳性癌症的car t细胞
EP4417623A1 (en) Ccr9 targeting moiety for the treatment of ccr9-positive cancer
HK40089985A (zh) 靶向爱泼斯坦-巴尔病毒的tcr-t细胞疗法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211022

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20211022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241107

R150 Certificate of patent or registration of utility model

Ref document number: 7590737

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150